20xx年醫(yī)學(xué)專(zhuān)題—第十三章-解熱鎮(zhèn)痛藥和非甾體抗炎藥-資料下載頁(yè)
2024-11-13 18:59本頁(yè)面
【正文】 5 Hbond acceptors 10,Lipinski CA et al. Adv Drug Deliv Rev, 1997, 23:325,Expansion of Rule 5： Polar Surface140197。2 Hbond donors and acceptors12 Rotary Bonds 10,Veber DF et al. J Med Chem. 2002, 45:26152623,Clardy J, Walsh C: Lessons from natural molecules. Nature, 2004, 432:829837.,Exception of Natural Products,Taxol,第五十七頁(yè)，共六十頁(yè)。,Lead Compound Drug Candidate,Druglike,Drugablity,Drugablity：Drug Candidate,Lipinski “Those compounds that have sufficiently acceptable ADME properties and sufficiently acceptable toxicity properties to survive through the completion of human Phase I clinical trials.”,第五十八頁(yè)，共六十頁(yè)。,Activity,Drugablity,Successful Drug Discovery,from 郭宗儒 老師(lǎoshī),第五十九頁(yè)，共六十頁(yè)。,內(nèi)容(n232。ir243。ng)總結(jié),第十二章 非甾體抗炎藥 （Nonsteroidal Antiinflammatory Drugs，NSAIDs）。1963年發(fā)現(xiàn)/ 1992年上市。Dr. Felix Hoffmann 與猶太人Arthur Eichengr252。n。羧基和羥基的修飾：成鹽、酰胺化和酯化。N苯環(huán)(běn hu225。n)在2,3,6位取代有較好的活性。1. 二芳基取代環(huán)類(lèi)。共性：具甲磺?；虬被酋；〈谋江h(huán)(běn hu225。n)。Rotary Bonds 10,第六十頁(yè)，共六十頁(yè)
試題試卷相關(guān)推薦
鄂ICP備17016276號(hào)-1